Mega $590 Million-Plus Block Deal Unfolding in Mankind Pharma; 3 PE Funds Considering Stake Sale!
In a financial spectacle, Mankind Pharma is currently at the center of a colossal block deal, surpassing a staggering $590 million. Sources reveal that three prominent private equity (PE) funds, namely Kris Capital, Capital Group, and Everbridge Partners, are contemplating a strategic move to divest a significant stake in Pharma through the block deal route.
While specific details of this high-profile transaction are yet to be disclosed, industry insiders suggest that the trio of investors aims to trim down a minimum of $592 million worth of shares in Pharma. Insiders hint that the deal could potentially reach a substantial size, potentially hovering around $677 million, considering larger options on the table.
According to sources, the combined stake sale by the three investors is estimated to be around 6.9% for the base deal, and for the upsized option, their collective stake is projected to be 7.9%. Although the identities of these investors remain undisclosed, the market is buzzing with speculation regarding the potential impact of this substantial block deal.
Market experts suggest that the minimum price per share for the block deal is set at INR 1785.65, a 7% discount from Pharma’s closing price of INR 1920.05 per share on December 11. This strategic move indicates a calculated decision by the PE funds to capitalize on the current market dynamics, potentially unlocking value for both the funds and the pharmaceutical giant.
Notably, the stock of Mankind Pharma has experienced a robust 30% surge in the past six months, gaining significant momentum since its impressive debut in the domestic stock markets on May 9.
While the trio of private equity investors remains tight-lipped about their identities, industry insiders suggest that investment banks Kotak Mahindra Capital and IIFL Capital have been advising on the proposed block deal.
The ongoing blockbuster deal in Mankind Pharma hints at a significant shift in the ownership structure of this pharmaceutical powerhouse. As details unfold, market analysts are keenly observing how this move might impact Mankind Pharma’s market standing and strategic direction. The pharmaceutical industry, known for its resilience and consistent growth, is witnessing yet another intriguing chapter in its financial narrative.
मैनकाइंड फार्मा में मेगा $590 मिलियन से अधिक की ब्लॉक डील; 3 पीई फंड बेच सकते हैं हिस्सेदारी!
मैनकाइंड फार्मा का स्टॉक पिछले छह महीनों में 30 फीसदी बढ़ा है. 9 मई को घरेलू शेयर बाजारों में इसकी जोरदार शुरुआत हुई।
तीन निजी इक्विटी फंडों का एक समूह, अर्थात् क्रिस कैपिटल, कैपिटल ग्रुप और एवरब्रिज पार्टनर्स, ब्लॉक डील रूट के माध्यम से मैनकाइंड फार्मा में कम से कम 592 मिलियन डॉलर की हिस्सेदारी कम करना चाह रहे हैं, उद्योग के कई सूत्रों ने डिजिटलवर्ल्डन्यूज़ को बताया। उपरोक्त व्यक्तियों में से एक ने कहा, “आधार सौदे के आकार पर, ये तीन निवेशक लगभग 592 मिलियन डॉलर मूल्य की हिस्सेदारी बेचना चाह रहे हैं। बड़े आकार के विकल्प को ध्यान में रखते हुए, सौदे का आकार 677 मिलियन डॉलर तक जा सकता है।” एक दूसरे व्यक्ति ने Digitalworldnewz को बताया कि आधार आकार पर बिक्री के लिए संयुक्त हिस्सेदारी 6.9 प्रतिशत होगी और अपसाइज़ विकल्प के लिए, तीन निवेशकों द्वारा पतला संयुक्त हिस्सेदारी आकार 7.9 प्रतिशत होगा। एक तीसरे व्यक्ति ने Digitalworldnewz को बताया कि निवेश बैंक कोटक महिंद्रा कैपिटल और IIFL कैपिटल प्रस्तावित ब्लॉक डील के लिए सलाहकार के रूप में कार्य कर रहे थे।
उन्होंने कहा कि 1785.65 रुपये प्रति शेयर का न्यूनतम मूल्य 11 दिसंबर को मैनकाइंड फार्मा के 1920.05 रुपये प्रति शेयर के बंद मूल्य से सात प्रतिशत कम है।
उपरोक्त तीनों व्यक्तियों ने नाम न छापने की शर्त पर Digitalworldnewz से बात की। Digitalworldnewz को 3 निजी इक्विटी निवेशकों या बैंकरों से तत्काल टिप्पणी नहीं मिल सकी।
मैनकाइंड फार्मा का स्टॉक पिछले छह महीनों में 30 फीसदी बढ़ा है. 9 मई को शेयर बाजार में इसकी जोरदार शुरुआत हुई। कंपनी का 4,326 करोड़ रुपये का आईपीओ किसी घरेलू फार्मा खिलाड़ी द्वारा सबसे बड़े आईपीओ में से एक था, क्योंकि ग्लैंड फार्मा ने 2020 में 6,480 करोड़ रुपये के इश्यू के साथ बाजार में अपनी शुरुआत की थी।
Plus block deal in Mankind Pharma
In a significant development in the financial landscape, a mega block deal, exceeding a staggering $590 million, is reportedly underway in Mankind Pharma. This maneuver is expected to witness the sale of stakes by three prominent private equity (PE) funds, marking a strategic shift in the ownership dynamics of the pharmaceutical giant.
The precise details of this high-profile transaction are yet to be unveiled, but the scale of the deal has already sent ripples through the financial sector. Mankind Pharma, a key player in the pharmaceutical industry, has been a beacon of success and innovation. The involvement of three PE funds signals a potential realignment of the company’s shareholding structure, introducing fresh perspectives and strategies.
The pharmaceutical sector, renowned for its resilience and steady growth, has been a magnet for strategic investments. The decision by these PE funds to divest their stakes in Mankind Pharma implies a calculated move, potentially unlocking value for both the funds and the company. It could be indicative of a broader trend wherein investors reevaluate their portfolios, capitalizing on opportunities that align with evolving market dynamics.
The names of the specific private equity funds involved in this deal are yet to be disclosed, adding an element of intrigue to the unfolding narrative. Such a significant block deal is likely to draw the attention of industry analysts, investors, and stakeholders keen on deciphering the implications for Mankind Pharma’s future trajectory.
While block deals of this magnitude are not uncommon in the dynamic world of finance, the pharmaceutical sector, being at the forefront of global health concerns, garners heightened attention. Mankind Pharma, known for its commitment to quality healthcare solutions, is likely to navigate this transition with strategic acumen, ensuring that the essence of its mission remains intact.
The aftermath of this mega deal could potentially redefine the competitive landscape within the pharmaceutical industry. It may set the stage for Mankind Pharma to explore new avenues of growth, research, and development, aligning with the ever-evolving demands of the healthcare sector.
As the finer details emerge, the market will keenly watch how this block deal unfolds and its ramifications on Mankind Pharma’s market standing. The pharmaceutical giant’s ability to adapt, innovate, and sustain its commitment to providing accessible healthcare solutions will likely remain at the core of its success, regardless of shifts in ownership dynamics.
In conclusion, the mega $590 million-plus block deal in Mankind Pharma, coupled with the potential exit of three private equity funds, adds an intriguing chapter to the pharmaceutical industry’s narrative. The repercussions of this deal, both for Mankind Pharma and the broader market, will be closely monitored, shedding light on the evolving strategies and dynamics within the realm of healthcare investments.